Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients

NCT01129336 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

First or Second Line HER2-negative Breast Cancer
Metastatic Disease Without Bone Metastasis

Interventions

DRUG: Zoledronic acid
DRUG: Standard Therapy

Sponsor

Novartis Pharmaceuticals